Guardant Health, Inc. (GH): Price and Financial Metrics

Guardant Health, Inc. (GH): $17.45

0.29 (-1.63%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

B

GH Price/Volume Stats

Current price $17.45 52-week high $41.06
Prev. close $17.74 52-week low $17.40
Day low $17.40 Volume 2,146,600
Day high $17.97 Avg. volume 1,708,842
50-day MA $21.73 Dividend yield N/A
200-day MA $28.86 Market Cap 2.12B

GH Stock Price Chart Interactive Chart >

GH POWR Grades

  • GH scores best on the Growth dimension, with a Growth rank ahead of 74.42% of US stocks.
  • GH's strongest trending metric is Quality; it's been moving up over the last 26 weeks.
  • GH ranks lowest in Momentum; there it ranks in the 7th percentile.

GH Stock Summary

  • Equity multiplier, or assets relative to shareholders' equity, comes in at 12.59 for GUARDANT HEALTH INC; that's greater than it is for 94.17% of US stocks.
  • As for revenue growth, note that GH's revenue has grown 24.38% over the past 12 months; that beats the revenue growth of 81.01% of US companies in our set.
  • GUARDANT HEALTH INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -13.11%, greater than the shareholder yield of just 18.97% of stocks in our set.
  • Stocks that are quantitatively similar to GH, based on their financial statements, market capitalization, and price volatility, are JAGX, OCUL, TVTX, CERS, and APLS.
  • GH's SEC filings can be seen here. And to visit GUARDANT HEALTH INC's official web site, go to guardanthealth.com.

GH Valuation Summary

  • GH's price/sales ratio is 6; this is 172.73% higher than that of the median Healthcare stock.
  • Over the past 64 months, GH's price/sales ratio has gone down 48.

Below are key valuation metrics over time for GH.

Stock Date P/S P/B P/E EV/EBIT
GH 2023-12-29 6.0 14.0 -7.4 -9.5
GH 2023-12-28 6.1 14.4 -7.6 -9.7
GH 2023-12-27 6.2 14.5 -7.6 -9.8
GH 2023-12-26 6.3 14.8 -7.8 -9.9
GH 2023-12-22 6.3 14.9 -7.8 -10.0
GH 2023-12-21 6.0 14.1 -7.5 -9.6

GH's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • GH has a Quality Grade of C, ranking ahead of 48.47% of graded US stocks.
  • GH's asset turnover comes in at 0.158 -- ranking 71st of 81 Healthcare stocks.
  • 500 - Internal server error

The table below shows GH's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.158 0.665 -0.174
2021-03-31 0.166 0.662 -0.187
2020-12-31 0.199 0.677 -0.197
2020-09-30 0.244 0.683 -0.205
2020-06-30 0.249 0.677 -0.147
2020-03-31 0.258 0.683 -0.108

GH Price Target

For more insight on analysts targets of GH, see our GH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $167.39 Average Broker Recommendation 1.27 (Strong Buy)

Guardant Health, Inc. (GH) Company Bio


Guardant Health, Inc., a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA. The company also provides LUNAR-1 for recurrence detection in cancer survivors; and LUNAR-2 for early detection of cancer in higher risk individuals. Guardant Health, Inc. was founded in 2011 and is based in Redwood City, California.


GH Latest News Stream


Event/Time News Detail
Loading, please wait...

GH Latest Social Stream


Loading social stream, please wait...

View Full GH Social Stream

Latest GH News From Around the Web

Below are the latest news stories about GUARDANT HEALTH INC that investors may wish to consider to help them evaluate GH as an investment opportunity.

Guardant Health (NASDAQ:GH) shareholders have endured a 78% loss from investing in the stock three years ago

Guardant Health, Inc. ( NASDAQ:GH ) shareholders should be happy to see the share price up 13% in the last month. But...

Yahoo | December 28, 2023

Guardant Health Announces $90.7 Million Registered Direct Offering with Baillie Gifford

PALO ALTO, Calif., December 21, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that it has entered into a common stock purchase agreement with Baillie Gifford on behalf of accounts that it manages for the sale of 3,387,446 shares of its common stock in a registered direct offering at an offering price of $26.77 per share.

Yahoo | December 21, 2023

Blood-Based Colorectal Cancer CRC Screening Market Likely to Benefit From FDA's Panel Surprise Advisory Possibility: Analyst

Tuesday, Guardant Health Inc (NASDAQ: GH) announced that the FDA's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is tentatively scheduled to review the premarket approval application (PMA) for its Shield blood test to screen for colorectal cancer on March 28, 2024. Guardant Health submitted the final module of its PMA for Shield on March 10, 2023. The submission includes data from the ECLIPSE study, an over 20,000-patient registrational study evaluating the perf

Yahoo | December 20, 2023

Guardant Health to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

PALO ALTO, Calif., December 20, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco.

Yahoo | December 20, 2023

Guardant Health Announces Tentative Date of FDA Advisory Panel Review of Shield™ Blood Test

PALO ALTO, Calif., December 19, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is tentatively scheduled to review the premarket approval application (PMA) for the company’s Shield™ blood test to screen for colorectal cancer on March 28, 2024. The date and details of the meeting are subject to confirmation by the FDA and publ

Yahoo | December 19, 2023

Read More 'GH' Stories Here

GH Price Returns

1-mo -22.17%
3-mo -30.81%
6-mo -33.17%
1-year -32.76%
3-year -88.01%
5-year -79.49%
YTD -35.49%
2023 -0.55%
2022 -72.81%
2021 -22.39%
2020 64.93%
2019 107.87%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!